Pneumococcal Vaccines

Ron Dagan, Shalom Ben-Shimol

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Pediatric vaccination against invasive pneumococcal disease (IPD) made a breakthrough in 2000 when a 7-valent pneumococcal conjugate vaccine was licensed. Subsequently, the spectrum was to introduce 10- and 13-valent conjugate vaccines PCV10 and PCV 13, which cover most of the IPD serotypes in children in developed countries. Those vaccines are highly effective against IPD caused by the vaccine serotypes, and are now part of infant immunization programs in most European countries and elsewhere. While effective against IPD, the conjugate vaccines have much less efficacy against pneumococcal pneumonia which remains a major cause of childhood mortality globally.

Original languageAmerican English
Title of host publicationPediatric Vaccines and Vaccinations
Subtitle of host publicationA European Textbook: Second Edition
Pages223-247
Number of pages25
ISBN (Electronic)9783030771737
DOIs
StatePublished - 1 Jan 2021

All Science Journal Classification (ASJC) codes

  • General Immunology and Microbiology
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • General Medicine

Fingerprint

Dive into the research topics of 'Pneumococcal Vaccines'. Together they form a unique fingerprint.

Cite this